InvestorsHub Logo
Followers 233
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: sstyles post# 304291

Saturday, 10/10/2020 12:26:46 PM

Saturday, October 10, 2020 12:26:46 PM

Post# of 428690
It's directly on Marksman page. BB


We have consulted on patent issues related to the following pharmaceutical drugs and related technologies:

Vascepa® (Amarin, $AMRN)



https://www.markmanadvisors.com/consulting

I believe Amarin/Marksman failed to connect 'motive' of table cropping in Kurabayashi...and this is why it wasn't argued. Our Amicus dug into Heinecke and shows the motivation behind the cropping of table and legend.

Notice how the Marksman leaves out Heinecke testimony.....It was a big moment in developing our argument after finding Heinecke impeach himself regarding Kurabayashi LDL. It's reasonable to assume this was just missed by Amarin attorney that where just too focused on secondary crap.

BB


If you're not good at being yourself, then maybe that's being yourself!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News